# Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study

> **NCT01280747** · — · TERMINATED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 42 (actual)

## Conditions studied

- Fibromyalgia
- Painful Diabetic Peripheral Neuropathy

## Interventions

- **OTHER:** prior authorization
- **OTHER:** no prior authorization
- **OTHER:** prior authorization
- **OTHER:** no prior authorization

## Key facts

- **NCT ID:** NCT01280747
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01280747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01280747, "Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01280747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*